Respiratory distress syndrome (RDS) causes significant hypoxia in extremely low birth weight (ELBW) infants. We report an ELBW infant with RDS and pulmonary hypertension whose hypoxia did not respond to inhaled nitric oxide but improved with inhaled prostacyclin. We propose that inhaled prostacyclin alleviated the hypoxia by stimulating surfactant secretion. (2007) 27, 724-726; doi:10.1038/sj.jp.7211811
Background
Hypoxemia is a feature of respiratory distress syndrome. Patent ductus arteriosus (PDA) and persistent pulmonary hypertension of the newborn (PPHN) can exacerbate hypoxemia. Inhaled nitric oxide (iNO) is effective for treatment of PPHN in full-term infants by decreasing pulmonary vascular resistance, thereby decreasing right-to-left shunting and alleviating hypoxemia. Several case reports have similarly shown that inhaled prostacyclin (iPGI 2 ) is effective through pulmonary vasodilation in full-term and preterm infants with PPHN. [1] [2] [3] [4] [5] Hypoxemia in our patient was refractory to iNO but improved with iPGI 2 . We propose that this response may be due to a physiological mechanism different from pulmonary vasodilatation.
Case A 25-week gestational age female weighing 820 g had Apgar scores of 4 and 5 at 1 and 5 min, respectively. She was intubated and given surfactant for respiratory distress, placed on dopamine and transferred to our hospital. On admission, her PaO 2 /FiO 2 was 93 and oxygenation index (OI) was 4.5 with synchronized intermittent mechanical ventilation (SIMV) mode (Babylog 8000 ventilator, Draeger Medical Inc., Telford, PA, USA). A few hours after admission, her OI increased to 16, PaO 2 /FiO 2 decreased to 40 and the right ventricular systolic pressure (RVSP)/blood pressure (BP) was 100% with a right-to-left shunt across a PDA and patent foramen ovale. The RVSP, estimated by Doppler tricuspid velocity signal, was taken as a measure of pulmonary systolic pressure in the absence of pulmonary outflow obstruction, and was expressed as a ratio to the systemic systolic pressure (RVSP/BP) ( Figure 1 ). Inhaled NO was started at 10 p.p.m. (Figure 1 ). Her oxygenation improved briefly but later worsened. She was switched from SIMV to high-frequency oscillatory ventilation (HFOV; SensorMedics 3100A High Frequency Oscillatory Ventilator, Viasys Healthcare, Yorba Linda, CA, USA), while iNO was increased to 20 p.p.m. A repeat echocardiogram (ECHO)/Doppler tricuspid velocity showed RSVP/ BP decreased to 67% and left-to-right shunting at both PDA and patent foramen ovale (PFO) (Figure 1 ).
She subsequently developed pulmonary interstitial emphysema and on day 4 of life she developed right-sided pneumothorax (Figure 1 ), which was adequately drained. However, her hypoxemia continued to worsen, iPGI 2 was considered and informed consent from her parents was obtained. The infant was changed to SIMV to deliver iPGI 2 . Following the switch to SIMV from HFOV the mean airway pressure on the ventilator dropped causing the OI to decrease, but PaO 2 /FiO 2 remained unchanged ( Figure 1 ). iPGI 2 was started at 50 ng/kg/min 4 and iNO (25 p.p.m.) was continued. iPGI 2 was delivered using the miniHeart Lo-Flo nebulizer (Westmed Inc., Tuczon, AZ, USA; particle size around 2-3 mm). Seven hours after the infant received the first dose of iPGI 2 , her OI dropped from 12 to 4.7. Her FiO 2 decreased from 0.90 to 0.30, PaO 2 /FiO 2 increased from 56 to 63 but RSVP/BP increased from 67 to 80% (Figure 1 ). As the infant continued to improve iPGI 2 and iNO were tapered and stopped as shown in Figure 1 . Three days after iPGI 2 was stopped PaO 2 /FiO 2 decreased to 48 and RVSP/BP rose to 87%. Due to an absence of significant tricuspid regurgitation, serial RVSP could no longer be determined. However, the infant did continue to improve clinically. Later ECHOs showed a persistent large PDA, which was surgically ligated. The systemic BP improved during iPGI 2 treatment, and the platelet count remained stable. She was extubated on day 40 of life and discharged on day 122 of life on home oxygen therapy for chronic lung disease. At 5 months of age, supplemental oxygen was stopped. At 7 months, her growth and development were within expected limits.
Discussion
Inhaled NO is an effective therapy for PPHN in full-term infants, and it has significantly decreased the need for extracorporeal membrane oxygenation. 6 However, iNO therapy in preterm infants remains controversial due to safety concerns. During iNO therapy, the reaction of iNO with superoxide leads to the formation of nitrogen dioxide and peroxynitrite. The peroxynitrite radical is a strong oxidant and is more toxic than other oxidants, such as superoxide and hydroxyl radicals. 7 Peroxynitrite formation impairs the surfactant system by damaging the alveolar epithelium 8 and decreasing ATP content, thereby decreasing surfactant synthesis. 8 In a primate model of infant chronic lung disease, the yield of surfactant phospholipid was 33% lower and surfactant protein SP-C was 54% lower in the iNO-treated group compared to the control group. 9 In many previous studies, the dose of iNO used in preterm infants has been 5-10 p.p.m. 10, 11 The initial dose of iNO was 10 p.p.m. When our patient deteriorated, this dose was later increased to 25 p.p.m. in the hope of obtaining a response. The higher levels of iNO may have led to elevated levels of peroxynitrite, leading to either a decrease or a frank inactivation of surfactant in the patient, exacerbating her hypoxemia.
Prostacyclin is an arachiadonic acid metabolite formed in the vascular endothelium and is a potent vasodilator with anti-inflammatory effects. Intravenous PGI 2 has successfully been used to treat pulmonary hypertension.
12 iPGI 2 acts locally, avoiding the systemic effects of hypotension and rebound hypertension seen with intravenous use, and has been successfully used in infants to treat PPHN. [1] [2] [3] [4] [5] Inhaled PGI 2 has been shown in rat alveolar type II cells (ATII) to enhance surfactant formation when lungs are stretched. Under normal conditions, surfactant production increases when ATII undergo stretch. 13 In ATII cells treated with iPGI 2 and iloprost, a longer acting PGI 2 analog, surfactant production increased 68 and 150%, respectively, compared to cells that underwent stretch alone. 13 Enhanced surfactant function in extremely low birth weight (ELBW) infants decreases alveolar collapse, which improves ventilation perfusion mismatch, leading to increased oxygenation. Alternatively, iNO and iPGI 2 may have caused pulmonary vasodilation by increasing cyclic 3 0 ,5 0 guanosine monophosphate and cyclic adenosine 3 0 ,5 0 monophosphate levels, respectively. The combined use of these drugs may be successful in treating pulmonary hypertension when a single drug fails. 14 However, the improvement in hypoxemia in our patient did not correlate with improvement in RVSP/BP and pulmonary vasodilation. Previous reports of neonates treated with iPGI 2 have shown significant improvement in oxygenation without demonstrating an improvement in RVSP. [1] [2] [3] [4] [5] Hence, it is likely that increased surfactant production resulting from stimulation of ATII by iPGI 2 was in part responsible for improvement in oxygenation in this ELBW infant with significant lung disease. We acknowledge that several of our interventions are known to improve hypoxemia. In addition, we did not collect tracheal aspirate samples to show increased surfactant secretion. Future studies regarding efficacy, safety (increased incidence of PDA ligation and so on) and pharmacokinetics of iPGI 2 therapy in ELBW infants are needed. Till then, this therapy should be considered experimental. 
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